Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | WNT3A | P56704 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2417326 | 0.89 | EPHX2 (0.44) | NPY5RRORCMAP4K4WNT3ALMNA | |
| SCHEMBL2423074 | 0.86 | WNT3A (0.46) | MAP4K4WNT3AUSP30DEGS1 | |
| SCHEMBL14019243 | 0.82 | NPY5R (0.75) | NPY5RCYP11B2TP53USP30 | |
| SCHEMBL2318660 | 0.81 | NPY5R (0.52) | NPY5RUSP30DEGS1TDO2 | |
| SCHEMBL2318895 | 0.80 | RORC (0.47) | RORCCYP11B2LMNAUSP30 | |
| SCHEMBL2316027 | 0.78 | WNT3A (0.52) | WNT3A | |
| SCHEMBL14018580 | 0.75 | NPY5R (0.62) | NPY5RTP53WNT3AUSP30 | |
| SCHEMBL14332260 | 0.74 | NPY5R (0.67) | NPY5RWNT3A | |
| SCHEMBL14333150 | 0.74 | NPY5R (0.63) | NPY5RWNT3AUSP30 | |
| SCHEMBL14332254 | 0.73 | NPY5R (0.62) | NPY5RWNT3AUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| EP-2352730-A2 | BIOLOGICALLY ACTIVE AMIDES | H. Lundbeck A/S (DK) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010053861-A2 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010053861-A2 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | NPY5R, NPY1R, NPY2R | NPY5R 1/4885RORC 1044/4885CYP11B2 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.